Table 1. Clinicopathologic characteristics of the study sample.

	All N = 176	Major/medium N = 45	Minor N = 59	Not depressed N = 72
Age (yrs)
Median [range]	49.5 [28,80]	51 [30,80]	50 [30,76]	48 [28,75]
Menopausal status	N = 166	N = 43	N = 54	N = 69
Premenopausal	50 (28.4)	9 (20.0)	17 (28.8)	24 (33.3)
Postmenopausal	116 (65.9)	34 (75.6)	37 (62.7)	45 (62.5)
BMI	N = 175	N = 45	N = 59	N = 71
Median [range]	24.1 [16.7,33.2]	24.2 [16.7,31.3]	24.0 [18.8,30.5]	24.1 [17.7,33.2]
Tumor size (cm)	N = 102	N = 27	N = 37	N = 38
Median [range]	2.35 [0.7-6.0]	2.50 [1.2-5.1]	2.0 [0.8-6.0]	2.75 [0.7-6.0]
Lymph node Met
Negative	36 (20.4)	11 (24.5)	10 (16.9)	15 (20.8)
Positive	114 (64.8)	28 (62.2)	41 (69.5)	45 (62.5)
Unknown	26 (14.8)	6 (13.3)	8 (13.6)	12 (16.7)
ER
Positive	99 (56.3)	29 (64.4)	34 (57.6)	36 (50.0)
Negative	77 (43.7)	16 (35.6)	25 (42.4)	36 (50.0)
PR
Positive	84 (47.7)	25 (55.6)	33 (55.9)	26 (36.1)
Negative	92 (52.3)	20 (44.4)	26 (44.1)	46 (63.9)
HER-2
Positive	42 (23.9)	7 (15.6)	10 (16.9)	25 (34.7)
Negative	112 (63.6)	32 (71.1)	43 (72.9)	37 (51.4)
Unknown	22 (12.5)	6 (13.3)	6 (10.2)	10 (13.9)
Histologic type
Ductal	140 (79.6)	36 (80.0)	46 (78.0)	58 (80.6)
Lobular	12 (6.8)	4 (8.9)	3 (5.1)	5 (6.9)
Others	24 (13.6)	5 (11.1)	10 (16.9)	9 (12.5)
BDFS
<24 months	64 (36.4)	11 (24.4)	20 (33.9)	33 (45.8)
≥24 months	112 (63.6)	34 (75.6)	39 (66.1)	39 (54.2)
Lung M
Positive	67 (38.1)	18 (40.0)	20 (33.9)	29 (40.3)
Negative	109 (61.9)	27 (60.0)	39 (66.1)	43 (59.7)
Liver M
Positive	71 (40.3)	14 (31.1)	27 (45.8)	30 (41.7)
Negative	105 (59.7)	31 (68.9)	32 (54.2)	42 (58.3)
Bone M
Positive	114 (64.8)	26 (57.8)	36 (61.0)	51 (70.8)
Negative	62 (35.2)	19 (42.2)	23 (39.0)	21 (29.2)